Earlier this month, over 21,000 researchers, clinicians, patients, and other stakeholders gathered at the AACR Annual Meeting 2023 to discuss the latest advances across the continuum of cancer research—from basic science to clinical research...
More programs address sexual health in cancer survivors, and survey suggests health insurance often doesn’t cover genetic tumor testing.
Historically, most cancer drugs have been tested separately in adults and children. For the approval of new drugs for children, researchers must ensure that doses are properly recalculated and new side effects do not...
“Are you ready to have a great meeting?” Robert Vonderheide, MD, DPhil, asked the nearly 11,000 attendees gathered in the plenary hall and virtually to watch the Opening Plenary Session of the AACR Annual...
People of African descent who receive genetic testing have fewer actionable mutations compared with white people—suggesting fewer available treatment options.
When Monica Bertagnolli, MD, was appointed director of the National Cancer Institute in 2022, she became the first woman to hold the post. A few months later, she became the first director to publicly...
Awareness of HPV link to cancer has declined, and more frequent COVID-19 boosters authorized for people who are immunocompromised.
Researchers use insights from behavioral economics to encourage taking recommended actions in health care.
New study finds drug combination after surgery helps prevent recurrence in liver cancer patients.
The 2015 approval of an immune checkpoint inhibitor for renal cell carcinoma (RCC) provided a much-needed new treatment option for patients with this disease, which causes almost 14,000 deaths each year, the majority of...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More